Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

BIOLOGICAL: pembrolizumab
DRUG: paclitaxel
DRUG: nab-paclitaxel
DRUG: liposomal doxorubicin
DRUG: capecitabine
DRUG: normal saline
DRUG: dextrose

Sponsor

Merck Sharp & Dohme LLC